Akoya BioSciences AKYA

$

9
8
7
6
5
4
3
2
1
0
0
9
8
7
6
5
4
3
2
1
0
0
.
9
8
7
6
5
4
3
2
1
0
0
+$0.03 (+2.24%)Past DayToday's Volume:
9
8
7
6
5
4
3
2
1
0
0
9
8
7
6
5
4
3
2
1
0
0
9
8
7
6
5
4
3
2
1
0
0
,
9
8
7
6
5
4
3
2
1
0
0
9
8
7
6
5
4
3
2
1
0
0
9
8
7
6
5
4
3
2
1
0
0

Relative Strength Index (RSI)

- The Relative Strength Index (RSI) is a momentum oscillator that measures the speed and change of price movements. It is typically used to identify overbought or oversold conditions in financial markets.

- The RSI is calculated using the following formula:

RSI = 100 - (100 / (1 + RS))

Where RS is the ratio of the average gains to the average losses over a specified period.

- The default time period used is 14 days.

- RSI values range between 0 and 100.

RSI values above 70 are considered overbought (indicating a potentially opportune time to sell)

RSI values below 30 are considered oversold (indicating a potentially opportune time to buy)

RSI is not a perfect indicator and should be used in conjunction with other technical analysis tools, this is for informational purposes only and is not a substitute for professional financial advice.

About

Business overview of Akoya BioSciences (AKYA)
Akoya Biosciences Inc is a life sciences technology company. It is delivering spatial biology solutions focused on transforming discovery, clinical research and diagnostics. Its PhenoCycler (formerly CODEX) and PhenoImager (formerly Phenoptics) platforms, reagents, software, and services, It offer end-to-end solutions to perform tissue analysis and spatial phenotyping across the full continuum from discovery through translational and clinical research and diagnostics.

Key Insights

Critical company metrics and information

  • Latest Closing Price

    $1.59

  • Market Cap

    $78.82 Million

  • Price-Earnings Ratio

    -7.57

  • Total Outstanding Shares

    49.57 Million Shares

  • Total Employees

    330

  • Dividend

    No dividend

  • IPO Date

    April 16, 2021

  • SIC Description

    Laboratory Analytical Instruments

  • Primary Exchange

    NASDAQ

  • Type

    Common Stock

  • Headquarters

    100 campus drive, Marlborough, MA, 01762

  • Homepage

    https://www.akoyabio.com

Historical Stock Splits

Execution DateSplit Amount
No Historical Stock Splits

Cash Flow Statement

July 1, 2024 to September 30, 2024
MetricValue
Net Cash Flow$3.61 Million
Net Cash Flow From Operating Activities$-9.26 Million
Net Cash Flow From Financing Activities$-150,000
Net Cash Flow From Financing Activities, Continuing$-150,000
Net Cash Flow, Continuing$3.61 Million
Net Cash Flow From Operating Activities, Continuing$-9.26 Million

Income Statement

July 1, 2024 to September 30, 2024
MetricValue
Other Operating Expenses$927,000
Income Tax Expense/Benefit$44,000
Preferred Stock Dividends And Other Adjustments$0
Income/Loss From Continuing Operations After Tax$-10.53 Million
Basic Earnings Per Share$-0.21
Diluted Earnings Per Share$-0.21

Comprehensive Income

July 1, 2024 to September 30, 2024
MetricValue
Comprehensive Income/Loss Attributable To Parent$-10.51 Million
Other Comprehensive Income/Loss Attributable To Parent$20,000
Comprehensive Income/Loss Attributable To Noncontrolling Interest$0
Other Comprehensive Income/Loss$-10.51 Million
Comprehensive Income/Loss$-10.51 Million

Balance Sheet

July 1, 2024 to September 30, 2024
MetricValue
Inventory$25.21 Million
Cash$39.30 Million
Long-term Debt$75.90 Million
Other Non-current Liabilities$12.45 Million
Noncurrent Liabilities$88.35 Million
Other Non-current Assets$30.29 Million

Historical Dividends

Announcement DatePayment DateRecord DateAmountFrequency
No historical dividends

Recent Headlines From The Web

Latest news, press releases, and media coverage about AKYA from trusted financial sources
    All TickersEarnings CalendarNews ArticlesAbout UsPrivacy & Cookies Info

    ⓒ 2025 Financhle. All Rights Reserved.